AKTOB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AKTOB (AKTOB).
Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.
| Metabolism | Hepatic via CYP3A4 enzyme system; major metabolites include AM1, AM9, and AM4N. |
| Excretion | Renal: 70-80% unchanged; biliary/fecal: 10-15% as metabolites. |
| Half-life | Terminal elimination half-life is 8-12 hours; prolonged in renal impairment (up to 20-30 hours in anuria). |
| Protein binding | 20-30% primarily to albumin. |
| Volume of Distribution | 0.25-0.4 L/kg; indicates distribution primarily in extracellular fluid. |
| Bioavailability | Intramuscular: approximately 90%; oral: not absorbed (0% due to degradation in GI tract). |
| Onset of Action | Intravenous: within 5-10 minutes; intramuscular: 15-30 minutes. |
| Duration of Action | Approximately 6-8 hours for antimicrobial effect; may be extended in renal dysfunction. |
| Action Class | Aminoglycosides |
| Brand Substitutes | Tobreb 80mg Injection, Tycin 80mg Injection, Tarabin 80mg Injection, Eltol 80mg Injection, Tobo Injection |
Adults: 10 mg orally once daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | GFR 30-89 mL/min: no adjustment; GFR 15-29 mL/min: 5 mg once daily; GFR <15 mL/min or dialysis: 2.5 mg once daily. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not established for children <18 years. |
| Geriatric use | No specific dose adjustment; monitor for hypotension and renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AKTOB (AKTOB).
| Breastfeeding | Not recommended during breastfeeding. M/P ratio unknown; potential infant exposure via milk. |
| Teratogenic Risk | First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; monitor for fetal growth restriction and oligohydramnios. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and fetal growth via ultrasound. Assess amniotic fluid volume regularly. |
■ FDA Black Box Warning
Increased risk of lymphomas and other malignancies, particularly of the skin. Increased susceptibility to infections. Cyclosporine can cause nephrotoxicity and hepatotoxicity.
| Serious Effects |
Hypersensitivity to cyclosporine or any component of the formulation, abnormal renal function, uncontrolled hypertension, malignancies, concurrent use with PUVA or UVB therapy in psoriasis.
| Precautions | Nephrotoxicity, hepatotoxicity, hypertension, hyperkalemia, neurotoxicity, increased risk of infections and malignancies, anaphylaxis (IV formulation). |
| Food/Dietary | No significant food interactions. Avoid alcohol while taking this medication. |
Loading safety data…
| Fertility Effects | May impair fertility in females (anovulation) and males (sperm abnormalities) based on animal data; clinical significance unknown. |
| Clinical Pearls |
| AKTOB is a beta-lactam antibiotic; monitor for hypersensitivity reactions, especially in patients with penicillin allergy. Adjust dose in renal impairment (CrCl <30 mL/min). Administer by slow IV infusion over 3-5 minutes or as directed. Observe for signs of Clostridioides difficile infection. |
| Patient Advice | Complete the full course of therapy even if symptoms improve. · Report any signs of allergic reaction such as rash, itching, or difficulty breathing immediately. · Inform your doctor if you have kidney problems or are on dialysis. · This medication may cause diarrhea; do not treat with anti-diarrheal medications without consulting your doctor. · Store at room temperature away from moisture and heat. |